NIPH Clinical Trials Search

Study of Mirogabalin and pregabalin to Improve Limb nEuropathy

Basic Information

Recruitment status	Recruiting
Health condition(s) or Problem(s) studied	Breast cancer
Date of first enrollment	16/03/2026
Target sample size	48
Countries of recruitment
Study type	Interventional
Intervention(s)	Pregabalin or mirogabalin will be administered as therapeutic agents for peripheral neuropathy.

Outcome(s)

Primary Outcome	NRS (Numerical Rating Scale)
Secondary Outcome	CTCAE ver6.0, PRO-CTCAE

Key inclusion & exclusion criteria

Age minimum	Not applicable
Age maximum	Not applicable
Gender	Both
Include criteria	1)Patients who have received perioperative chemotherapy for breast cancer and have developed chemotherapy-induced peripheral neuropathy (CIPN). 2) Patients who are able to complete a patient diary and questionnaire survey. 3) Patients aged between 18 and 80 years at the time of obtaining informed consent. 4) Patients who have provided written informed consent to participate in the study.
Exclude criteria	1) Patients who have peripheral neuropathy prior to the initiation of chemotherapy. 2) Patients who are currently taking pregabalin or mirogabalin besilate. 3) Patients who are pregnant or breastfeeding. 4) Patients who are currently participating in another clinical trial or clinical study. 5) Patients whom the principal investigator or subinvestigator deems inappropriate for inclusion in the study.